Qilu Pharmaceutical's Carboplatin Injection Becomes First in China to Pass Generic Drug Consistency Evaluation

On June 21, the NMPA official website showed that Qilu Pharmaceutical's Carboplatin Injection passed the generic drug consistency evaluation as the first in China. Data from Menet shows that the sales of Carboplatin Injection in Chinese public medical institutions reached nearly 700 million yuan in 2021, increasing by 29.65% year-on-year.

Carboplatin Injection is a second-generation platinum-based antineoplastic drug and a commonly used chemotherapy agent in clinical practice, primarily for small cell lung cancer, ovarian cancer, testicular tumors, head and neck cancer, and malignant lymphoma.

Data from MiNe Network shows that in recent years, the domestic market for carboplatin injection in China has shown a significant upward trend. In 2021, terminal sales in Chinese urban public hospitals, county public hospitals, urban community health centers, and township health clinics (referred to as Chinese public medical institutions) approached 700 million yuan, with a year-on-year increase of 29.65%. Among these, the carboplatin injection and injectable carboplatin from Qilu Pharmaceutical Co., Ltd. combined to account for nearly 60% of the market share.

Sales of Carboplatin Injection in Chinese Public Medical Institutions (Unit: Ten Thousand Yuan)

Source: Terminal Competition Pattern of Public Medical Institutions in China, Menet

Currently, only three companies in China hold the production approval for carboplatin injection, including Qilu Pharmaceutical, Shanghai Creation Pharmaceutical, and Bristol-Myers Squibb. Additionally, nine companies have the production approval for injectable carboplatin. To date, only Qilu Pharmaceutical's carboplatin injection has passed the consistency evaluation.

Platinum-based antitumor drugs are an important part of Qilu Pharmaceutical's oncology field. Currently, Qilu Pharmaceutical has a range of platinum products from the first generation to the third generation, including Cisplatin Injection, Carboplatin Injection, Nedaplatin for Injection, and Oxaliplatin Injection, which can effectively meet different clinical treatment needs.

It is worth mentioning that Qilu Pharmaceutical's four platinum-based anti-tumor drugs, including Cisplatin Injection, Carboplatin Injection, Nedaplatin for Injection, and Oxaliplatin Injection, have all passed/been considered to pass the consistency evaluation, which is beneficial for enhancing the market competitiveness of the company’s anti-tumor products.

Data source: MiNeiNet database

Original Title: 700 Million Injectables, Qilu First to Pass Evaluation